Triple Negative Breast CancerPhase 3NCT07879911
A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer
A Phase 3 study testing Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043 and Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin） in people with Triple Negative Breast Cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd..
Trial summary
This is a randomized, controlled, open-label, multicenter study. Eligible participants are patients with unresectable locally recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Triple Negative Breast Cancer
- What is being tested?
- Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043 and Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin）
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 550 participants
- Where
- No sites listed yet
- Study dates
- 30 Nov 2026to 30 May 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 and ≤ 75 years at the time of signing the informed consent form, with no restriction on sex.
- Histologically and/or cytologically confirmed triple negative breast cancer (TNBC) meeting both of the following criteria: a) Human epidermal growth factor receptor 2 (HER2) negative; b) Estrogen receptor (ER) negative and progesterone receptor (PR) negative.
- De novo metastatic disease, or unresectable recurrent and/or metastatic disease occurring after completion of curative intent therapy.
- No prior systemic anti tumor therapy for unresectable recurrent or metastatic disease.
- PD L1 expression determined by the sponsor designated central laboratory using tumor tissue collected at screening. Participants must meet either: a) PD L1 negative expression (CPS < 10); OR b) PD L1 positive expression (CPS ≥ 10).
- At least one measurable lesion per RECIST version 1.1.
Show all 13Show fewer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Expected survival of at least 12 weeks.
- Deemed by the investigator to be suitable for one of the investigator's choice chemotherapy regimens (paclitaxel, nab paclitaxel, capecitabine, eribulin, or carboplatin).
- Adequate organ and bone marrow function (no transfusion, recombinant human thrombopoietin, or colony stimulating factor within 2 weeks prior to randomization).
- Participants must have recovered from all toxicities attributable to prior therapies (recovered to Grade ≤ 1 per CTCAE Version 6.0, or otherwise meeting protocol specified entry criteria).
- Serum pregnancy test negative within 7 days prior to randomization for women of child bearing potential.
- Voluntarily agrees to participate in this study, provides signed informed consent, and is able to comply with protocol required visits and procedures.
Who cannot join
- Diagnosis of another malignancy within 3 years prior to randomization.
- Presence of spinal cord compression, clinically active brain metastase.
- Presence of cardiovascular and cerebrovascular diseases or cardiovascular cerebrovascular risk factors.
- 4 History of non infectious interstitial lung disease (ILD) or non infectious pneumonitis requiring steroid therapy.
- 5 Clinically significant pulmonary impairment secondary to underlying pulmonary disease.
- 6 Tumor invasion into adjacent vital organs and blood vessels. 7 Severe infection occurring within 4 weeks prior to randomization. 8 History of esophageal and gastric varices, severe ulcer, gastrointestinal perforation, gastrointestinal obstruction, intra abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to randomization.
Show all 18Show fewer
- 9 Active or well documented prior history of inflammatory bowel disease. 10 Uncontrolled systemic disease as judged by the investigator. 11 Participants with active viral hepatitis; positive hepatitis C virus (HCV) with HCV RNA above the lower limit of quantification of the assay.
- 12 Positive human immunodeficiency virus (HIV) test or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
- 13 Known hypersensitivity to active pharmaceutical ingredients or excipients of study drug.
- 14 Known history of allogeneic solid organ transplantation or allogeneic hematopoietic stem cell transplantation.
- 15 Pregnant or breastfeeding women. 16 Prior receipt of B7 H3 targeted therapy; prior irinotecan, topotecan, or any chemotherapy agents targeting topoisomerase I (including ADCs).
- 17 Prior treatment with the same agent as the investigator selected chemotherapy.
- 18 Live vaccine administered within 4 weeks before randomization, or planned administration of live vaccine during study treatment.
- 19 Insufficient washout period for prior anti tumor therapy before the first dose of study drug.
- 20 Chronic concomitant use of systemic corticosteroids or other immunosuppressive agents.
- 21 Local or systemic disease unrelated to malignancy, or diseases/symptoms secondary to tumor.
- 22 Any condition that, in the investigator's opinion, would interfere with the evaluation of study drug, participant safety, or interpretation of study results, or any other condition rendering the participant unsuitable for study participation as assessed by the investigator.
- 23 Systemic administration of strong CYP3A4 / CYP2C8 inhibitors or strong inducers, or OATP1B1 / OATP1B3 inhibitors within 14 days prior to the first dose of study drug, or requiring continued systemic use of such agents during study treatment.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Randomized, Open-Label, Multicenter Phase III Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
This is a randomized, controlled, open-label, multicenter study. Eligible participants are patients with unresectable locally recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy. Participants may be PD-L1 negative; or PD-L1 positive with disease recurrence after PD-1/PD-L1 inhibitor therapy in the neoadjuvant/adjuvant setting; or PD-L1 positive who cannot tolerate PD-1/PD-L1 inhibitor therapy due to other underlying comorbidities.
Approximately 550 participants will be enrolled and randomized at a 1:1 ratio to the experimental group or the control group. All enrolled participants will continue study treatment until BICR-confirmed disease progression, no further clinical benefit as judged by the investigator, unacceptable toxicity, withdrawal of informed consent, loss to follow-up, death, or end of study, whichever occurs first.
Upon discontinuation of study treatment, participants will complete the end-of-treatment (EOT) visit and safety follow-up. Survival visits will be performed every 3 months (±14 days) after the last study drug administration to collect participants' survival status and information regarding subsequent anti-tumor therapies
- Conditions
- Triple Negative Breast Cancer
- Being tested
- Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043, Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin）
- Medical subject headings
- Triple Negative Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043Biological
Add details that will distinguish this intervention from other interventions in this or another clinical study.
Participants in the experimental group will receive SYS6043, administered on Day 1 of each cycle，Q3W.
Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin）Drug
Add details that will distinguish this intervention from other interventions in this or another clinical study.
Paclitaxel (90 mg/m², intravenous, Days 1, 8, and 15 of each 4 week cycle [Q4W]; or 80 mg/m², intravenous, Days 1, 8, and 15 of each 3 week cycle [Q3W]); Nab paclitaxel (100 mg/m², intravenous, Days 1, 8, and 15, Q4W); Capecitabine (1000 1250 mg/m², orally, twice daily on Days 1 14, Q3W); Eribulin (1.4 mg/m², intravenous, Days 1 and 8, Q3W); Carboplatin (administered on Day 1 at an area under the curve [AUC] of 6, Q3W).
| Study group | Role | What they receive |
|---|---|---|
| SYS6043 | Experimental | Not described Receives: Biological: Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043 |
| Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin） | Active comparator | Not described Receives: Drug: Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin） |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression Free Survival (PFS) Assessed by BICR per RECIST 1.1
Progression free survival is defined as the time from randomization to the first documented disease progression per RECIST version 1.1 or death from any cause, whichever occurs first. Disease progression is centrally reviewed by a blinded independent imaging review committee to eliminate assessment bias.
Measured: Up to approximately 5 years
Overall Survival (OS)
Overall survival is defined as the time from randomization to death from any cause. For participants who are not deceased, survival time will be censored at the last known date the participant was known to be alive.
Measured: Up to approximately 5 years
Secondary outcomes (9)
Objective Response Rate (ORR) assessed by BICR/Investigator per RECIST 1.1
Objective Response Rate (ORR) is the proportion of participants achieving confirmed complete response (CR) or partial response (PR) per RECIST version 1.1. ORR will be evaluated by both Blinded Independent Central Review (BICR) and investigator (INV).
Measured: Up to approximately 5 years
Disease Control Rate (DCR) assessed by BICR/Investigator per RECIST 1.1
Disease Control Rate (DCR) is defined as the percentage of participants with confirmed complete response (CR), partial response (PR), or stable disease (SD) per RECIST version 1.1. DCR will be evaluated by both Blinded Independent Central Review (BICR) and investigator (INV).
Measured: Up to approximately 5 years
Duration of Response (DoR) assessed by BICR/Investigator per RECIST 1.1
Duration of Response (DoR) is defined as the time from the date of first documented confirmed objective response (CR or PR) per RECIST version 1.1 to the date of documented disease progression or death from any cause, whichever occurs first. DoR will be evaluated by both Blinded Independent Central Review (BICR) and investigator (INV)
Measured: Up to approximately 5 years
Time To Response (TTR) assessed by BICR/Investigator per RECIST 1.1
Time To Response (TTR) is defined as the time from randomization to the date of first documented confirmed objective response (CR or PR) per RECIST version 1.1 among participants who achieve an objective response. TTR will be evaluated by both Blinded Independent Central Review (BICR) and investigator (INV).
Measured: Up to approximately 5 years
Time to First Subsequent Therapy(TFST)
Time to First Subsequent Therapy (TFST) is defined as the time from randomization to the start date of the first subsequent anti-cancer therapy after discontinuation of randomized study treatment, or death from any cause, whichever occurs first.
Measured: Up to approximately 5 years
Time to Second Subsequent Therapy (TSST)
Time to Second Subsequent Therapy (TSST) is defined as the time from randomization to the start date of the second subsequent anti-cancer therapy after discontinuation of randomized study treatment, or death from any cause, whichever occurs first.
Measured: Up to approximately 5 years
Incidence and Titer of Anti Drug Antibody (ADA) against SYS6043, and Incidence of Neutralizing Antibody (NAb), if applicable
The incidence and titer of anti drug antibody (ADA) against SYS6043 will be evaluated from serum samples. The incidence of neutralizing antibody (NAb) will be assessed among ADA positive participants, if applicable.
Measured: Up to approximately 5 years
Patient-Reported Quality of Life Scores Evaluated by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Participants' quality of life will be assessed using the symptom domain scales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is a 30-item patient-reported questionnaire. All transformed subscale scores range from 0 to 100. For the functional scales and global health status scale, higher scores represent better functioning and quality of life. For symptom scales, higher scores indicate more severe symptoms (worse outcome).
Measured: Up to approximately 5 years
Patient Reported Quality of Life Scores Evaluated by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module 42(EORTC QLQ BR42).
Participants' quality of life will be assessed using the symptom domain scales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module 42 (EORTC QLQ-BR42). This is a 42-item breast cancer-specific patient-reported questionnaire. All transformed subscale scores range from 0 to 100. For functional scales, higher scores represent better functioning. For symptom scales, higher scores indicate more severe symptoms (worse outcome）
Measured: Up to approximately 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2026
- Study start30 Nov 2026 (estimated)
- Primary completion30 Nov 2028 (estimated)
- Study completion30 May 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Triple Negative Breast CancerStudies of the same condition, open and under way.
- More trials run by CSPC Megalith Biopharmaceutical Co.,Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a randomized, open-label, parallel-group, active-controlled study with a permitted crossover design. Participants are randomly assigned in a 1:1 ratio to receive either SYS6043 or investigator's choice of chemotherapy. Participants in the control arm who experience first disease progression may crossover to receive SYS6043 treatment if eligibility criteria are met. Participants in the experimental arm will not crossover after disease progression.
- Masking
- None (open label)
- Enrolment
- 550 participants (estimated)
Sponsor and investigators
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07879911
- Sponsor's protocol ID
- SYS6043-006
- Status last verified
- Oct 2026
- First submitted
- 28 Sep 2026
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Open-Label, Multicenter Phase III Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
- ClinicalTrials.gov ID
- NCT07879911
- Acronym / sponsor ID
- SYS6043-006
- Conditions
- Triple Negative Breast Cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 550 participants (estimated)
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry (pharma, biotech, devices)
- Study start
- 30 Nov 2026 (estimated)
- Primary completion
- 30 Nov 2028 (estimated)
- Study completion
- 30 May 2029 (estimated)
- First posted
- 19 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, controlled, open-label, multicenter study. Eligible participants are patients with unresectable locally recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy. Participants may be PD-L1 negative; or PD-L1 positive with disease recurrence after PD-1/PD-L1 inhibitor therapy in the neoadjuvant/adjuvant setting; or PD-L1 positive who cannot tolerate PD-1/PD-L1 inhibitor therapy due to other underlying comorbidities.
Approximately 550 participants will be enrolled and randomized at a 1:1 ratio to the experimental group or the control group. All enrolled participants will continue study treatment until BICR-confirmed disease progression, no further clinical benefit as judged by the investigator, unacceptable toxicity, withdrawal of informed consent, loss to follow-up, death, or end of study, whichever occurs first.
Upon discontinuation of study treatment, participants will complete the end-of-treatment (EOT) visit and safety follow-up. Survival visits will be performed every 3 months (±14 days) after the last study drug administration to collect participants' survival status and information regarding subsequent anti-tumor therapies
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a randomized, open-label, parallel-group, active-controlled study with a permitted crossover design. Participants are randomly assigned in a 1:1 ratio to receive either SYS6043 or investigator's choice of chemotherapy. Participants in the control arm who experience first disease progression may crossover to receive SYS6043 treatment if eligibility criteria are met. Participants in the experimental arm will not crossover after disease progression.
| Arm | Type | Receives |
|---|---|---|
| SYS6043 | Experimental | Biological: Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043 |
| Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin） | Active comparator | Drug: Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin） |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Age ≥ 18 and ≤ 75 years at the time of signing the informed consent form, with no restriction on sex.
- Histologically and/or cytologically confirmed triple negative breast cancer (TNBC) meeting both of the following criteria: a) Human epidermal growth factor receptor 2 (HER2) negative; b) Estrogen receptor (ER) negative and progesterone receptor (PR) negative.
- De novo metastatic disease, or unresectable recurrent and/or metastatic disease occurring after completion of curative intent therapy.
- No prior systemic anti tumor therapy for unresectable recurrent or metastatic disease.
- PD L1 expression determined by the sponsor designated central laboratory using tumor tissue collected at screening. Participants must meet either: a) PD L1 negative expression (CPS < 10); OR b) PD L1 positive expression (CPS ≥ 10).
Key exclusion criteria (18 listed)
- Diagnosis of another malignancy within 3 years prior to randomization.
- Presence of spinal cord compression, clinically active brain metastase.
- Presence of cardiovascular and cerebrovascular diseases or cardiovascular cerebrovascular risk factors.
- 4 History of non infectious interstitial lung disease (ILD) or non infectious pneumonitis requiring steroid therapy.
- 5 Clinically significant pulmonary impairment secondary to underlying pulmonary disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043Add details that will distinguish this intervention from other interventions in this or another clinical study. Participants in the experimental group will receive SYS6043, administered on Day 1 of each cycle，Q3W. | Biological | SYS6043 |
| Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin）Add details that will distinguish this intervention from other interventions in this or another clinical study. Paclitaxel (90 mg/m², intravenous, Days 1, 8, and 15 of each 4 week cycle [Q4W]; or 80 mg/m², intravenous, Days 1, 8, and 15 of each 3 week cycle [Q3W]); Nab paclitaxel (100 mg/m², intravenous, Days 1, 8, and 15, Q4W); Capecitabine (1000 1250 mg/m², orally, twice daily on Days 1 14, Q3W); Eribulin (1.4 mg/m², intravenous, Days 1 and 8, Q3W); Carboplatin (administered on Day 1 at an area under the curve [AUC] of 6, Q3W). | Drug | Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin） |
Primary outcome
Progression Free Survival (PFS) Assessed by BICR per RECIST 1.1
Time frame: Up to approximately 5 years
Progression free survival is defined as the time from randomization to the first documented disease progression per RECIST version 1.1 or death from any cause, whichever occurs first. Disease progression is centrally reviewed by a blinded independent imaging review committee to eliminate assessment bias.
Overall Survival (OS)
Time frame: Up to approximately 5 years
Overall survival is defined as the time from randomization to death from any cause. For participants who are not deceased, survival time will be censored at the last known date the participant was known to be alive.
9 secondary outcomes
Objective Response Rate (ORR) assessed by BICR/Investigator per RECIST 1.1
Time frame: Up to approximately 5 years
Disease Control Rate (DCR) assessed by BICR/Investigator per RECIST 1.1
Time frame: Up to approximately 5 years
Duration of Response (DoR) assessed by BICR/Investigator per RECIST 1.1
Time frame: Up to approximately 5 years
Time To Response (TTR) assessed by BICR/Investigator per RECIST 1.1
Time frame: Up to approximately 5 years
Time to First Subsequent Therapy(TFST)
Time frame: Up to approximately 5 years
Time to Second Subsequent Therapy (TSST)
Time frame: Up to approximately 5 years
Incidence and Titer of Anti Drug Antibody (ADA) against SYS6043, and Incidence of Neutralizing Antibody (NAb), if applicable
Time frame: Up to approximately 5 years
Patient-Reported Quality of Life Scores Evaluated by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Time frame: Up to approximately 5 years
Patient Reported Quality of Life Scores Evaluated by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module 42(EORTC QLQ BR42).
Time frame: Up to approximately 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
Related trials for Triple Negative Breast Cancer
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 2
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
RecruitingPhase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Breast Neoplasms, Breast Cancer
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043 and Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin） in people with Triple Negative Breast Cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jian Zhang (021-64175590, syner2000@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression Free Survival (PFS) Assessed by BICR per RECIST 1.1 (time frame: Up to approximately 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.